Augustas Beiša1, Mindaugas Kvietkauskas2, Virgilijus Beiša2, Mindaugas Stoškus3, Elvyra Ostanevičiūtė4, Eugenijus Jasiūnas5, Laimonas Griškevičius3,6, Kęstutis Strupas2. 1. Centre of Abdominal Surgery, Vilnius University, Santariškių 2, 08406, Vilnius, Lithuania. augustas.beisa@santa.lt. 2. Centre of Abdominal Surgery, Vilnius University, Santariškių 2, 08406, Vilnius, Lithuania. 3. Centre of Haematology, Oncology and Transfusion Medicine, Vilnius University, Vilnius, Lithuania. 4. Centre of Laboratory Medicine, Vilnius University, Vilnius, Lithuania. 5. Mykolas Romeris University, Vilnius, Lithuania. 6. Centre of Internal, Family Medicine and Oncology, Vilnius University, Vilnius, Lithuania.
Abstract
PURPOSE: This study aims to determine the utility of the Bethesda category and its association with BRAF mutation in prediction of the papillary thyroid cancer (PTC) stage. METHODS: A prospective study analyzed patients who had ultrasound-suspicious thyroid nodules, underwent FNA and cytological examination, and were classified according to the Bethesda system. Patients from Undetermined Significance Or Follicular Lesion Of Undetermined Significance (AUS/FLUS), Follicular Neoplasm or Suspicious for a Follicular Neoplasm (FN/SFN), Suspicious for Malignant Cells (SMC), and Positive for Malignant Cells (PMC) groups were examined for the BRAF mutation and had a thyroid surgery. Demographical and histological features and stage of the disease were evaluated for PTC patients in accordance with the Bethesda category and its association with BRAF mutation. RESULTS: Three hundred eight of all patients underwent operation. One hundred forty-three (46.4%) of them were diagnosed with PTC. In 14 (9.8%) PTC cases, FNA biopsies were classified as AUS/FLUS, 23 (16.1%) as FN/SFN, 41 (28.7%) as SMC, and 65 (45.5%) as PMC. I-II stages of PTC were diagnosed for 88 (61.5%) patients and III-IVA for 55 (38.5%). Patients from the SMC and PMC groups had larger tumors, higher incidence of lymph node metastases, classical PTC type, B-type Raf (BRAF) positive, and III-IVA stage cancer, than patients from the AUS/FLUS and FN/SFN groups. When comparing 27 (18.9%) BRAF-negative patients from the AUS/FLUS and FN/SFN groups with 116 (81.1%) BRAF-negative patients from the SMC and PMC groups and all BRAF-positive patients, the prediction of more aggressive histological features and stage was slightly improved. CONCLUSIONS: Higher Bethesda categories are associated with higher stages of PTC. Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction.
PURPOSE: This study aims to determine the utility of the Bethesda category and its association with BRAF mutation in prediction of the papillary thyroid cancer (PTC) stage. METHODS: A prospective study analyzed patients who had ultrasound-suspicious thyroid nodules, underwent FNA and cytological examination, and were classified according to the Bethesda system. Patients from Undetermined Significance Or Follicular Lesion Of Undetermined Significance (AUS/FLUS), Follicular Neoplasm or Suspicious for a Follicular Neoplasm (FN/SFN), Suspicious for Malignant Cells (SMC), and Positive for Malignant Cells (PMC) groups were examined for the BRAF mutation and had a thyroid surgery. Demographical and histological features and stage of the disease were evaluated for PTC patients in accordance with the Bethesda category and its association with BRAF mutation. RESULTS: Three hundred eight of all patients underwent operation. One hundred forty-three (46.4%) of them were diagnosed with PTC. In 14 (9.8%) PTC cases, FNA biopsies were classified as AUS/FLUS, 23 (16.1%) as FN/SFN, 41 (28.7%) as SMC, and 65 (45.5%) as PMC. I-II stages of PTC were diagnosed for 88 (61.5%) patients and III-IVA for 55 (38.5%). Patients from the SMC and PMC groups had larger tumors, higher incidence of lymph node metastases, classical PTC type, B-type Raf (BRAF) positive, and III-IVA stage cancer, than patients from the AUS/FLUS and FN/SFN groups. When comparing 27 (18.9%) BRAF-negative patients from the AUS/FLUS and FN/SFN groups with 116 (81.1%) BRAF-negative patients from the SMC and PMC groups and all BRAF-positive patients, the prediction of more aggressive histological features and stage was slightly improved. CONCLUSIONS: Higher Bethesda categories are associated with higher stages of PTC. Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction.
Authors: Linwah Yip; Electron Kebebew; Mira Milas; Sally E Carty; Thomas J Fahey; Sareh Parangi; Martha A Zeiger; Yuri E Nikiforov Journal: Surgery Date: 2010-12 Impact factor: 3.982
Authors: Yuri E Nikiforov; David L Steward; Toni M Robinson-Smith; Bryan R Haugen; Joshua P Klopper; Zhaowen Zhu; James A Fagin; Mercedes Falciglia; Katherine Weber; Marina N Nikiforova Journal: J Clin Endocrinol Metab Date: 2009-03-24 Impact factor: 5.958
Authors: Allen S Ho; Evan E Sarti; Kunal S Jain; Hangjun Wang; Iain J Nixon; Ashok R Shaha; Jatin P Shah; Dennis H Kraus; Ronald Ghossein; Stephanie A Fish; Richard J Wong; Oscar Lin; Luc G T Morris Journal: Thyroid Date: 2014-03-10 Impact factor: 6.568
Authors: Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544
Authors: Whitney S Goldner; Trevor E Angell; Sallie Lou McAdoo; Joshua Babiarz; Peter M Sadow; Fadi A Nabhan; Christian Nasr; Richard T Kloos Journal: Thyroid Date: 2019-09-27 Impact factor: 6.568